argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026 Biotech Investing
Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026 Life Science Investing
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026 Life Science Investing
PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics Life Science Investing
Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call Life Science Investing
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT Pharmaceutical Investing
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy Life Science Investing
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026 Life Science Investing
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026 Life Science Investing
Seer Board of Directors Issues Letter to Shareholders Setting the Record Straight Life Science Investing
